MeJa Methyl Jasmonate
Description: <b>Methyl jasmonate (MeJa)</b> is a well-known plant stress hormone. <br>
Pathways:<br>
-Causes mitochondrial dysfunction by inducing the release of cytochrome c, which leads to caspase activation.<br>
- ↓ glycolysis via hexokinase-VDAC disruption<br>
- ↑ ROS in cancer cells<br>
-MJ can lead to cell cycle arrest, thereby inhibiting the proliferation of cancer cells<br>
<p><b>Methyl Jasmonate</b> — Methyl jasmonate (MeJa, MJ) is a naturally occurring, hydrophobic, volatile oxylipin and methyl ester of jasmonic acid that functions as a plant stress-response phytohormone. Pharmacologically, it is an experimental small-molecule metabolic and mitochondria-targeting anticancer agent rather than an approved anticancer drug. Its most distinctive proposed cancer-selective mechanism is disruption of the mitochondrial hexokinase-II–VDAC complex, linking inhibition of glycolytic energy metabolism to mitochondrial dysfunction and cell death. Anticancer evidence remains predominantly preclinical.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Disrupts the mitochondrial HK-II–VDAC complex, detaching hexokinase-II from mitochondria, impairing glycolytic coupling, reducing ATP production and promoting mitochondrial membrane permeabilization.</li>
<li>Induces mitochondrial dysfunction with ↓ mitochondrial membrane potential, cytochrome-c release and activation of intrinsic apoptotic signaling.</li>
<li>↑ ROS and oxidative stress, contributing to apoptosis and pro-death autophagy; ROS can activate DDIT3/CHOP–TNFRSF10B/DR5–caspase signaling.</li>
<li>Activates intrinsic and extrinsic apoptosis, including ↑ BAX/BCL-XS, caspase-8 and caspase-3 signaling and ↓ anti-apoptotic proteins such as survivin, XIAP and CFLAR in model-dependent settings.</li>
<li>Produces cell-cycle arrest and reduced proliferation, with the affected cell-cycle phase varying among tumor models.</li>
<li>Suppresses migration, invasion and angiogenic signaling in some tumor models, including ↓ Sp1–MMP14–VEGF signaling.</li>
<li>Can sensitize cancer cells to metabolic inhibitors, cisplatin, TRAIL and ionizing radiation in preclinical combination studies.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Human pharmacokinetic data relevant to anticancer dosing are essentially absent. MeJa is hydrophobic and poorly water-soluble, creating formulation and systemic-delivery constraints. Anticancer cell studies commonly require approximately 0.5–3 mM MeJa, although some signaling and anti-migratory effects occur at lower concentrations. Animal studies demonstrate that comparatively large systemic doses can be tolerated, but this does not establish clinically achievable or safe chronic human anticancer exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> This is a major translational limitation. Many direct cytotoxicity experiments use low-millimolar MeJa concentrations, substantially higher than the micromolar concentrations typical of potent pharmacologic agents. There is insufficient human PK evidence to show that sustained low-millimolar tumor concentrations can be achieved safely. Sub-cytotoxic effects on migration, invasion and angiogenic signaling have been reported around 0.05–0.2 mM in some models. More potent synthetic MeJa derivatives are therefore an active development strategy.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical. Evidence includes numerous cancer-cell studies and several animal tumor/metastasis models. Very limited exploratory topical human observations have been reported historically, but these do not constitute controlled anticancer trials. No established systemic anticancer indication, validated human anticancer dose, or regulatory approval exists. MeJa should therefore be classified as an experimental preclinical anticancer agent rather than an adjunct with demonstrated clinical efficacy.</p>
<h3>Methyl Jasmonate Cancer Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HK-II–VDAC mitochondrial coupling</td>
<td>HK-II mitochondrial binding ↓; VDAC association ↓; glycolytic coupling ↓</td>
<td>Less characterized; proposed selectivity relates partly to greater mitochondrial HK-II dependence in cancer</td>
<td>P-R</td>
<td>ATP production ↓; metabolic vulnerability ↑</td>
<td>Best-defined direct molecular mechanism. MeJa binds hexokinase and promotes detachment of mitochondria-associated hexokinase from VDAC.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial membrane integrity</td>
<td>Mitochondrial membrane potential ↓; cytochrome c release ↑; mitochondrial dysfunction ↑</td>
<td>Generally less affected in tested mammalian normal-cell models, but universal tumor selectivity is not established</td>
<td>P-R</td>
<td>Intrinsic apoptosis ↑; ATP depletion ↑</td>
<td>Closely coupled to HK-II–VDAC disruption and represents a central cytotoxic mechanism.</td>
</tr>
<tr>
<td>3</td>
<td>ROS oxidative stress</td>
<td>ROS ↑; H2O2 ↑ (model-dependent)</td>
<td>Variable and incompletely characterized</td>
<td>P-R</td>
<td>Oxidative stress ↑; apoptosis and autophagic cell death ↑</td>
<td>ROS scavenging can markedly suppress MeJa-induced apoptosis and autophagy in NSCLC models, supporting a causal role.</td>
</tr>
<tr>
<td>4</td>
<td>DDIT3–TNFRSF10B–caspase death signaling</td>
<td>DDIT3 ↑; TNFRSF10B ↑; CFLAR ↓; caspase activity ↑</td>
<td>Insufficient comparative evidence</td>
<td>R-G</td>
<td>Extrinsic apoptosis ↑</td>
<td>Well demonstrated in NSCLC; strongly ROS-dependent but not necessarily universal across tumor types.</td>
</tr>
<tr>
<td>5</td>
<td>BCL-2 family and caspase apoptosis</td>
<td>BAX/BCL-XS ↑; caspase-3 ↑; mitochondrial apoptosis ↑</td>
<td>Usually less cytotoxic in comparative cell studies</td>
<td>R-G</td>
<td>Apoptosis ↑</td>
<td>Intrinsic and extrinsic death pathways can operate simultaneously and are partly tumor-model dependent.</td>
</tr>
<tr>
<td>6</td>
<td>Glycolysis and cellular ATP</td>
<td>Glycolytic flux ↓; ATP ↓</td>
<td>Less pronounced where mitochondrial HK-II dependence is lower</td>
<td>P-R</td>
<td>Bioenergetic collapse ↑</td>
<td>Metabolic mechanism is especially relevant to highly glycolytic tumors and provides rationale for combination with 2-deoxyglucose and related metabolic inhibitors.</td>
</tr>
<tr>
<td>7</td>
<td>Autophagy</td>
<td>Autophagy ↑</td>
<td>Insufficient comparative evidence</td>
<td>R-G</td>
<td>Pro-death autophagy ↑ (context-dependent)</td>
<td>In NSCLC models, pharmacologic/autophagic studies indicate that the response contributes to rather than protects against MeJa cytotoxicity.</td>
</tr>
<tr>
<td>8</td>
<td>Cell-cycle and proliferation control</td>
<td>Cell-cycle arrest ↑; PCNA ↓; proliferation ↓</td>
<td>Generally smaller response in comparative studies</td>
<td>G</td>
<td>Growth inhibition ↑</td>
<td>G0/G1, S or other arrest patterns have been reported depending on tumor type and experimental conditions.</td>
</tr>
<tr>
<td>9</td>
<td>Survivin and XIAP anti-apoptotic signaling</td>
<td>Survivin ↓; XIAP ↓</td>
<td>Insufficient evidence</td>
<td>G</td>
<td>Apoptotic threshold ↓</td>
<td>Reported particularly in neuroblastoma and combination studies; may contribute to TRAIL and other treatment sensitization.</td>
</tr>
<tr>
<td>10</td>
<td>Migration and invasion</td>
<td>Migration ↓; invasion ↓; MMP14 ↓</td>
<td>Not established</td>
<td>G</td>
<td>Metastatic phenotype ↓</td>
<td>Observed at sub-cytotoxic concentrations in gastric cancer and melanoma models.</td>
</tr>
<tr>
<td>11</td>
<td>Sp1–MMP14–VEGF angiogenic signaling</td>
<td>Sp1 ↓; MMP14 ↓; VEGF ↓; angiogenic activity ↓</td>
<td>Direct endothelial effects become cytotoxic at high concentrations</td>
<td>G</td>
<td>Angiogenesis ↓ (dose-dependent)</td>
<td>Interpret cautiously: low micromolar concentrations produced complex angiogenic responses in endothelial models, whereas higher millimolar concentrations were toxic.</td>
</tr>
<tr>
<td>12</td>
<td>Chemosensitization</td>
<td>Cisplatin, TRAIL and metabolic-inhibitor cytotoxicity ↑ (model-dependent)</td>
<td>Limited comparative combination data</td>
<td>G</td>
<td>Combination efficacy ↑</td>
<td>Preclinical evidence includes cisplatin, TRAIL, 2-deoxyglucose and other cytotoxic agents; no validated clinical combination regimen exists.</td>
</tr>
<tr>
<td>13</td>
<td>Radiosensitization</td>
<td>X-ray cytotoxicity ↑; required radiation dose ↓ (model-dependent)</td>
<td>Insufficient comparative evidence</td>
<td>G</td>
<td>Radiation sensitivity ↑</td>
<td>Demonstrated in cervical cancer cell lines with X-rays and, less consistently, alpha-particle irradiation.</td>
</tr>
<tr>
<td>14</td>
<td>Clinical Translation Constraint</td>
<td>Effective direct cytotoxic concentrations frequently 0.5–3 mM</td>
<td>Human therapeutic window unknown</td>
<td>G</td>
<td>Clinical translatability ↓</td>
<td>Hydrophobicity, formulation, lack of human anticancer PK and predominance of millimolar in-vitro activity are major limitations. Human systemic efficacy has not been established.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>